EPAM Systems beat Q1 expectations but fell 5% on the day — and the wave of analyst target cuts that followed makes clear the Street is more worried about what comes next than relieved about what just happened.
The earnings print itself was better than feared. EPAM beat consensus EPS by roughly 11 cents. But Q2 guidance pointed toward a slower ramp in larger AI deals and extended sales cycles, and that was enough to trigger the broadest and most aggressive round of target reductions in recent memory. Goldman Sachs downgraded the stock outright to Neutral, slashing its price target from $215 to $110 — a cut of more than 48%. Citigroup, Truist, Wells Fargo, Guggenheim, Needham, Morgan Stanley, and Susquehanna all followed with their own reductions, with targets now clustered in the $110–$167 range. The consensus mean target has settled near $150, against a close of $99.23, but the velocity of those cuts tells a more cautious story than the residual implied upside suggests. With nine Buys and seven Holds on record, the formal consensus still leans positive — though the Goldman downgrade is a meaningful signal that the risk-reward is being reconsidered at the bellwether level.
Short sellers have been adding quietly into the weakness. SI hit 15.6% of free float on May 7 — up from 13.2% in late April, a jump of roughly two and a half percentage points in less than two weeks. That move coincides almost exactly with the spike in SI that followed the tariff-related turbulence of early April, when shorts similarly pushed above 15% before pulling back sharply around April 23. The pattern repeating itself is worth noting: each time the stock breaks lower on macro or guidance-related news, short interest reasserts itself in the 15–16% range. Borrow conditions remain loose, with a cost to borrow of just 0.48% — barely moved on the week — and availability at a comfortable level, meaning there is no current squeeze pressure to force a covering rally. The ORTEX short score of 66.2 ranks in the bottom decile of the universe, flagging elevated short conviction.
Options positioning has eased relative to where it was earlier this week. The put/call ratio reached 1.55 on May 7 — matching its 52-week high — before pulling back to 1.20 on May 8. That's still above the 20-day mean of 1.28, but the z-score has dropped to -0.34, meaning the most acute defensive positioning has partially unwound following the earnings release. The shift is subtle: options traders were heavily hedged into the print, and some of that protection has since been lifted. The overall tone remains cautious, with the PCR well elevated relative to where it was in late March and early April when the ratio was running below 0.90.
Valuation has compressed sharply. The trailing PE has dropped to 7.8x, down more than 2 points over the past 30 days, and the EV/EBITDA multiple has fallen to 4.3x. Those are low multiples for a business EPAM's management describes as broadening its organic growth in AI-native services. The bear case on valuation compression toward 7x PE in a prolonged downturn is therefore already partly in the price. Bulls will point to the forward EPS growth rank of 94th percentile and an EV/EBIT score of 94th percentile as evidence the stock is genuinely cheap on a forward basis. Bears counter with the geopolitical exposure, the shift to longer AI deal cycles, and the risk that top-line visibility remains limited — all of which are live concerns, as the guidance commentary confirmed.
The founder's shadow also hangs over the stock. Arkadiy Dobkin — Chairman, President and CEO — sold 30,082 shares at $133.26 on March 25, realising around $4 million. The stock has since fallen another 26% from that level. It is the most significant insider transaction in the recent window, and it came well above current prices. Capital Research meanwhile added over 1.4 million shares as of April 30, making it one of the more aggressive recent institutional additions. The divergence between the founder selling near $133 and an active manager accumulating through the drawdown captures the tension in this name well.
The next earnings date is May 21. With the guidance range now re-set lower and a Goldman downgrade fresh in the market, the setup heading into that event is one where the analyst community will be watching closely for any change in the AI deal ramp narrative — and whether the stock can find a floor after losing more than a quarter of its value in a single month.
See the live data behind this article on ORTEX.
Open EPAM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
